P atients with heart failure are frequently limited by exertional fatigue during both normal daily activities and maximal exercise testing.'-3 This exertional fatigue is usually attributed to skeletal muscle underperfusion, based on observations that patients with heart failure on average exhibit reduced cardiac output and leg blood flow responses to exercise. '-3 Recently, however, a number of skeletal muscle abnormalities have been detected in patients with heart failure, including abnormal metabolic responses to small muscle exercise,4-8 reduced mitochondrial-based enzymes,9'10 reduced mitochondrial volume,1" and muscle atrophy.12 It has also been observed that cardiac rehabilitation can improve the exercise capacity of patients with heart failure without improving leg blood flow.'3"14 These observations suggest that exertional fatigue in at least some patients with heart failure may be due to skeletal muscle changes rather than to inadequate skeletal muscle blood flow.
The present study was undertaken to determine if a subpopulation of patients with heart failure develops exertional fatigue due to skeletal muscle dysfunction rather than to reduced muscle flow. To examine this possibility, we measured cardiac output, leg blood flow, and lactate responses to exercise in a group of patients with heart failure and exertional fatigue. Similar measurements were obtained in a group of normal subjects. Flow and metabolic responses were then compared in the two groups to identify patients with leg fatigue and abnormal muscle lactate release but normal leg flow responses.
Methods
Patient Population
All exercise hemodynamic studies performed in our laboratory on compensated patients with heart failure were reviewed to identify those who exhibited peak exercise Vo2 levels .18 ml . mind . kg-' due to leg fatigue and who underwent insertion of a Swan-Ganz catheter and leg blood flow catheter. Most of these patients were undergoing investigational studies to examine the effect of acute therapeutic interventions; these studies have been reported previously.15-18 Patients with peripheral vascular disease were excluded. Patients with a history of excessive alcoholic intake were also excluded as alcohol is known to damage skeletal muscle.
The requirement that patients note marked leg fatigue during exercise did not lead to the exclusion of patients who also experienced dyspnea. During maximal exercise testing, nearly all patients with compensated heart failure report severe leg fatigue at peak exercise with varying levels of dyspnea.1-3 A total of 34 patients were identified. This group had an average age of 57±2 years (±SEM), mean left ventricular ejection fraction of 21+2%, and peak exercise Vo2 of 12±1 ml * min-m * kg`. All patients reported marked exertional fatigue at maximal exercise; none experienced chest pain. Thirty-one of the patients were male and three were female. Left ventricular dysfunction was attributed to coronary artery disease in 25 patients and to idiopathic cardiomyopathy in nine patients. All patients were taking furosemide, and all except two patients were receiving digoxin. Fourteen patients were taking some form of vasodilator therapy before the study (e.g., isosorbide dinitrate, prazosin, hydralazine, or captopril). All vasodilator therapy was discontinued at least 48 hours before the study. All patients also were optimally diuresed before the study; no patient had peripheral edema.
For comparison, six normal male subjects with normal exercise capacity (peak exercise Vo2, 25 + 2 ml . min' . kg-') were studied. The average age of the subjects was 45±2 years. These subjects had normal activity levels, were not involved in any training program, and were not taking any medications.
Protocol
On the day before the study, a trial maximal bicycle exercise test was performed to acquaint the patient with the exercise protocol. Exercise was performed on an upright mechanically braked bicycle ergometer (Monach) and begun at a work load of 20 
Techniques
Leg blood flow was determined as previously de- scribed."' [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] In brief, femoral vein flow was measured using a 50-cm SF thermodilution catheter with the thermistor at 2 cm and the injection port at 12 cm. Flow was determined using rapid injection of a 2.5-ml iced dextrose bolus injectate and a commercially available thermodilution computer (Elecath). Output curves were displayed on a strip-chart recorder to ensure an exponential decay curve. Flow determined using this system correlated closely with known flow rates (0.2-6.0 1/min, r=0.99) when evaluated using a closed-loop system in which 37°C H20 was continuously circulated through 7-mm polyethylene tubing using a roller pump. 
Normal Subjects
The control subjects were able to exercise to a peak Vo2 of 25.1+±1.6 ml* min' * kg'. Hemodynamic, metabolic, and leg flow responses to exercise are summarized in Tables 1 and 2 and Figure 1 . Exercise resulted in progressive increases in systemic Vo2, leg blood flow, and leg arteriovenous oxygen difference. Femoral venous lactate concentration typically increased in an exponential fashion, with levels increasing only modestly at 20-60 W followed by a more rapid increase at higher work loads. This pattern was paralleled by changes in the respiratory gas exchange ratio. Heart Failure Patients As a group, the patients with heart failure were able to exercise to a peak Vo2 of only 12.2+0.6 ml * min'.
kg-', significantly less than in the normal subjects (p<0.001). All patients experienced marked exertional fatigue at peak exercise. femoral venous lactate relations was almost threefold steeper in the patients than in the normal subjects (0.81±0.08 versus 0.33±0.07 mg* dl-' W-', p<0.002), whereas the intercepts were similar in the two groups (11±4 versus 9±1 mg/dl, p=NS). These early increases in femoral venous lactate in the patients were also associated with early increases in systemic lactate and in the respiratory gas exchange ratio ( Table 1) . The remaining 25 patients with heart failure exhibited reduced leg blood flow responses, increased leg arteriovenous oxygen differences, early lactate release, and reduced exercise capacity (Tables 1 and 2 ). Compared with these 25 patients, the nine patients with normal flow exhibited comparable ejection fractions (normal flow, 26±4%; low flow, 19±2%), supine resting cardiac indices (normal flow, 2.1±0.2 1. min.* m-2; low flow, 1.9±0.1 1 * min' * m-2), supine resting pulmonary wedge pressure (normal flow, 19±2 mm Hg; low flow, 23±2 mm Hg), ages (normal flow, 58±3 years; low flow, 57±2 years), duration of heart failure (normal flow, 21±8 months; low flow, 24±7 months), and time to the most recent hospitalization (normal flow, 7±2 months; low flow, 6±2 months) (all p=NS). Of particular note, femoral venous, systemic lactate, and respiratory gas exchange ratio responses to exercise were similar in the two groups (Tables 1 and 2 ). Patients with normal leg flow did exhibit lower pulmonary wedge pressures when they were at rest sitting on the bicycle (normal flow, 13±2 mm Hg; low flow, 20±2 mm Hg) (p<0.05), better cardiac output responses to exercise, and a tendency toward higher peak exercise Vo2 (normal flow, 14 .1±0.9 ml min1 -kg-'; low flow, 11.5±0.7 ml min-1 kg-') (p=0.0503). In addition, patients with normal leg flow tended to have lower levels of nonleg flow at peak exercise (normal flow, 2.0+0.7 1/min; low flow, 2.8±0. 3 1/min) (p=0.17); nonleg flow was calculated as the difference between the cardiac output and twice the leg flow measurement.
Discussion
Exertional fatigue in heart failure traditionally has been attributed to inadequate skeletal muscle blood flow, based on observations that cardiac output and leg blood flow responses to maximal exercise are on average reduced in patients with heart failure.1-3 Recently, we and others4-12 have described a number of skeletal muscle changes in patients with heart failure, including skeletal muscle atrophy, reduced mitochondrial-based enzymes, reduced mitochondrial size, increased type II fibers, and abnormal metabolic responses to forearm and calf exercise despite normal flow responses. Such observations have led many investigators to speculate that skeletal muscle changes may contribute to exercise intolerance in heart failure. However, it has also been reported that these muscle changes parallel changes in muscle flow and exercise capacity,1"119 leading to the assumption that muscle abnormalities occur concurrently with flow abnormalities and therefore primarily compound the effects of muscle underperfusion.
Results of the present study suggest that a significant proportion of patients with heart failure and typical exertional fatigue are in fact not limited by skeletal muscle underperfusion. Using a conservative estimate of normal leg flow, 26% of our patients with heart failure and significant exercise intolerance did not exhibit skeletal muscle underperfusion, as evidenced by a normal leg blood flow. Nevertheless, these patients exhibited abnormal lactate responses to exercise and leg fatigue, suggesting that they were limited by intrinsic skeletal muscle abnormalities.
The etiology of these muscle abnormalities was not specifically examined in the present study. However, it seems likely that muscle deconditioning and, possibly, malnutrition are important contributors; these conditions could trigger abnormal lactate release by a variety of mechanisms, including muscle atrophy with increased loading of each muscle fiber; increased activation of fast-twitch, glycolytic fibers; and heightened glycolytic activity due to enzymatic changes within muscle. Patients are frequently inactive. The muscle changes noted in patients have been observed in deconditioning normal subjects. 20 Cardiac rehabilitation has been shown to improve the maximal exercise capacity of patients and to improve muscle metabolic responses to exercise.13,14 Total caloric intake of patients is frequently reduced,12 and classic evidence of malnutrition is not uncommon. 21 The fact that one fourth of our patients appeared to be limited by skeletal muscle changes rather than by muscle underperfusion has several major clinical implications. First, it suggests that the presence of exertional fatigue, a reduced peak exercise Vo2, and an early anaerobic threshold should no longer be considered indicative of skeletal muscle underperfusion in patients with heart failure. How does one reconcile this conclusion with prior observations that both the anaerobic threshold and peak Vo2 correlate with cardiac output and leg blood flow responses to exercise in patients with heart failurel-3? Results of the present study are not inconsistent with these prior observations. The majority of patients examined in this study also exhibited re- One method of estimating leg blood flow during exercise is to measure cardiac output responses to exercise using a Swan-Ganz catheter. However, this approach has a higher complication rate than femoral venous catheterization and may provide misleading information. In addition, the patients in this study who exhibited normal leg blood flows also tended to deliver a greater proportion of their cardiac output to the legs during exercise, as evidenced by a lower nonleg blood flow at peak exercise. In such patients, evaluation of the cardiac output response to exercise would underestimate the actual leg blood flow response. Why such patients appear to have enhanced flow distribution to the leg is unclear, although one might speculate that arteriolar vasodilation in skeletal muscle is less impaired in these patients than in patients with reduced leg flow.
Ideally, a noninvasive technique should be available to identify patients with normal flow. One potential technique is near-infrared spectroscopy, a noninvasive method of assessing skeletal muscle hemoglobin oxygenation using near-infrared light. 24 We are currently evaluating the utility of this technique.
Whatever technique is developed, one key issue that will need to be addressed is the definition of normal leg blood flow. We used a conservative criterion to define normal leg blood flow during exercise. If a different criterion were used, such as mean normal flow +2 SD, close to 50% of the patients would have been identified as having normal leg flow. Further work is needed to define the optimal criteria for identifying patients with preserved muscle flow, i.e., flow levels that ensure adequate muscle oxygen delivery at a cellular level.
Several limitations of this study are worth noting. Leg blood flow is an index of blood flow to working skeletal muscle but also includes flow to nonmuscular tissue and to inactive muscle. Therefore, it is possible that flow to working muscle was actually reduced in the patients with normal flow, although this seems very unlikely. Second, it should be emphasized that demonstration of abnormal increases in femoral venous lactate with concurrent leg fatigue in the patients with normal flow does not prove that skeletal muscle metabolic abnormalities limit exercise. Abnormal release of lactate from the legs indicates abnormal muscle metabolism but not that lactate causes fatigue. In fact, reports from this and other laboratories suggest that lactate does not directly cause fatigue.25 Nevertheless, the demonstration of fatigue and lactate abnormalities in the presence of normal leg flow strongly suggests that muscle rather than flow abnormalities are limiting exercise.
In summary, results of this study suggest that >25% of patients with chronic heart failure and exertional fatigue are limited by skeletal muscle abnormalities rather than by skeletal muscle underperfusion.
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